Anti-CD20 Therapy Alters the Protein Signature in Experimental Murine AIH, but Not Exclusively towards Regeneration
Authors:
- Laura Elisa Buitrago-MolinaLBLaura Elisa Buitrago-Molina
- Janine DywickiJDJanine Dywicki
- Fatih NoyanFNFatih Noyan
- Lena SchepergerdesLSLena Schepergerdes
- Julia PietrekJPJulia Pietrek
- Maren LieberMLMaren Lieber
- Jerome SchlueJSJerome Schlue
- Michael P. MannsMMMichael P. Manns
- Heiner WedemeyerHWHeiner Wedemeyer
- Elmar JaeckelEJElmar Jaeckel
- Matthias Hardtke-WolenskiMatthias Hardtke-Wolenski
Open Access
Abstract
Background: Autoimmune hepatitis (AIH) is a chronic autoimmune inflammatory disease that usually requires lifelong immunosuppression. Frequent recurrences after the discontinuation of therapy indicate that intrahepatic immune regulation is not restored by current treatments. Studies of other autoimmune diseases suggest that temporary depletion of B cells can improve disease progression in the long term. Methods: We tested a single administration of anti-CD20 antibodies to reduce B cells and the amount of IgG to induce intrahepatic immune tolerance. We used our experimental murine AIH (emAIH) model and treated the mice with anti-CD20 during the late stage of the disease. Results: After treatment, the mice showed the expected reductions in B cells and serum IgGs, but no improvements in pathology. However, all treated animals showed a highly altered serum protein expression pattern, which was a balance between inflammation and regeneration. Conclusions: In conclusion, anti-CD20 therapy did not produce clinically measurable results because it triggered inflammation, as well as regeneration, at the proteomic level. This finding suggests that anti-CD20 is ineffective as a sole treatment for AIH or emAIH.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (BU2722/2-1, BU2722/2-3, HA 6880/2-1, HA 6880/2-3, KFO250; Project 7)
This publication has 62 references indexed in Scilit:
- Diagnosis and Management of Autoimmune HepatitisHepatology, 2010
- B-cell-directed therapies for autoimmune diseaseNature Reviews Rheumatology, 2009
- WNT1-inducible signaling protein–1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosisJournal of Clinical Investigation, 2009
- IL‐5‐overexpressing mice exhibit eosinophilia and altered wound healing through mechanisms involving prolonged inflammationImmunology & Cell Biology, 2008
- Role of PDGF in fibrotic diseases and systemic sclerosisRheumatology, 2008
- B-cell targeting in rheumatoid arthritis and other autoimmune diseasesNature Reviews Immunology, 2006
- Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosisAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2006
- Rituximab‐responsive CIDPEuropean Journal of Neurology, 2004
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Immunoglobulin on the surface of isolated hepatocytes is associated with antibody‐dependent cell‐mediated cytotoxicity and liver damageLiver International, 1987